HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Glucagon-Like Peptide-1 (GLP-1) Rescue Diabetic Cardiac Dysfuntions in Human iPSC-Derived Cardiomyocytes.

Abstract
Glucagon-like peptide-1 (GLP-1) can improve cardiac function and cardiovascular outcomes in diabetic cardiomyopathy; however, the beneficial effect of GLP-1 on human diabetic cardiomyocytes (DCMs) and its mechanism have not been fully elucidated. Here, the DCMs model by human-induced pluripotent stem cells-derived cardiomyocytes is developed. Two subtypes of GLP-1, GLP-17-36 and GLP-19-36 , are evaluated for their efficacy on the DCMs model. Diabetogenic condition is sufficient to induce most characteristics of diabetic cardiomyopathy in vitro, such as cardiac hypertrophy, lipid accumulation, impaired calcium transients, and abnormal electrophysiological properties. GLP-17-36 and GLP-19-36 can restore cardiomyocyte hypertrophic phenotype, impaired calcium transient frequency, abnormal action potential amplitude, depolarization, and repolarization velocity. Interestingly, RNA-seq reveals different pathways altered by GLP-17-36 and GLP-19-36 , respectively. Differentially expressed gene analysis reveals that possible targets of GLP-17-36 involve the regulation of mitotic nuclear division and extracellular matrix-receptor interaction, while possible targets of GLP-19-36 involve kinetochore assembly, and the complement and coagulation cascades. This study demonstrates the therapeutic effects of GLP-1 on human DCMs and provides a novel platform to unveil the cellular mechanisms of diabetic cardiomyopathy, shedding light on discovering better targets for novel therapeutic interventions.
AuthorsYing Zhou, Shuting Huang, Chengwu Li, Yue Qiao, Qing Liu, Taotao Chen, Jiaxian Wang, Yu Liu
JournalAdvanced biology (Adv Biol (Weinh)) Vol. 7 Issue 9 Pg. e2200130 (09 2023) ISSN: 2701-0198 [Electronic] Germany
PMID36373695 (Publication Type: Journal Article, Research Support, Non-U.S. Gov't)
Copyright© 2022 Wiley-VCH GmbH.
Chemical References
  • Glucagon-Like Peptide 1
  • glucagon-like peptide-1 (9-36)
Topics
  • Humans
  • Myocytes, Cardiac (metabolism)
  • Glucagon-Like Peptide 1 (pharmacology, metabolism, therapeutic use)
  • Induced Pluripotent Stem Cells (metabolism)
  • Diabetic Cardiomyopathies (drug therapy, genetics, metabolism)
  • Diabetes Mellitus (metabolism)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: